Cost-effectiveness of incretin therapies: a Canadian lens on diabetes, obesity, and emerging indications
Canadian Journal of Physiology and Pharmacology · 2026
DOI: 10.1139/cjpp-2025-0248 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Canadian Journal of Physiology and Pharmacology, 2026. Verfasst von Luke Awadalla und 3 weiteren Autor:innen. Beteiligte Einrichtung: Western University, London, ON, Canada. Hauptthemen laut MEDLINE: Incretins, Cost-Benefit Analysis, Diabetes Mellitus, Type 2, Obesity. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Incretin therapies have emerged as key interventions for glycemic control and weight reduction and are now among Canada’s costliest outpatient drug classes. This review synthesizes current clinical and economic evidence on the cost-effectiveness of incretin-based therapies. These include glucagon-like peptide-1 receptor agonists (GLP-1RAs; e.g., semaglutide) and dual agonists (e.g., tirzepatide) targeting both glucose-dependent insulinotropic polypeptide and GLP-1 receptors, in patients with type 2 diabetes mellitus or for weight loss. We review data from clinical trials and recent Canadian and international economic models, identify emerging indications, and discuss limitations in current health-technology assessment frameworks. Implications for Canadian reimbursement are highlighted, with attention to price, patient selection, and outcome considerations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Western University, London, ON, Canada.
- Queen's University, Kingston, ON, Canada.
- Women's College Hospital Research and Innovation Institute, Toronto, ON, Canada.
- Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.
ORCID-Profile: Mina Tadrous
Zitieren
APA
Awadalla, L., Iskander, S., Chu, C., & Tadrous, M. (2026). Cost-effectiveness of incretin therapies: a Canadian lens on diabetes, obesity, and emerging indications. Canadian Journal of Physiology and Pharmacology. https://doi.org/10.1139/cjpp-2025-0248
Vancouver
Awadalla L, Iskander S, Chu C, Tadrous M. Cost-effectiveness of incretin therapies: a Canadian lens on diabetes, obesity, and emerging indications. Canadian Journal of Physiology and Pharmacology. 2026. doi:10.1139/cjpp-2025-0248
BibTeX
@article{Awadalla2026,
author = {Awadalla, Luke and Iskander, Siena and Chu, Cherry and Tadrous, Mina},
title = {Cost-effectiveness of incretin therapies: a Canadian lens on diabetes, obesity, and emerging indications},
journal = {Canadian Journal of Physiology and Pharmacology},
year = {2026},
doi = {10.1139/cjpp-2025-0248}
}
EUVIMED